

# Martin Å imkoviÄ•

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7339395/publications.pdf>

Version: 2024-02-01

61  
papers

1,580  
citations

516710

16  
h-index

330143

37  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1796  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	10.7	448
2	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2849-2861.	1.6	235
3	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
4	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1031-1043.	10.7	76
5	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. , 2022, 1, .		66
6	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	3.5	62
7	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
8	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab &lt;i>&gt; versus &lt;i>&gt; chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120.	3.5	53
9	Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 1278-1282.	0.8	25
10	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	1.4	23
11	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	1.4	22
12	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	5.2	22
13	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. <i>Blood</i> , 2021, 138, 70-70.	1.4	20
14	Venous thromboembolism in patients with chronic lymphocytic leukemia. <i>Thrombosis Research</i> , 2015, 136, 1082-1086.	1.7	19
15	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2020, 136, 11-12.	1.4	19
16	Alternating <sc>R&lt;/sc>CHOP</sc> and <sc>R</sc>â€œcytarabine is a safe and effective regimen for transplantâ€œineligible patients with a newly diagnosed mantle cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 110-115.	1.7	18
17	Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. <i>Blood</i> , 2014, 124, 4670-4670.	1.4	16
18	Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen. <i>Blood</i> , 2020, 136, 39-41.	1.4	13

#	ARTICLE	IF	CITATIONS
19	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
20	Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. <i>International Journal of Hematology</i> , 2012, 96, 594-599.	1.6	11
21	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. <i>European Journal of Haematology</i> , 2013, 90, 479-485.	2.2	11
22	Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases. <i>Acta OncolĀgica</i> , 2012, 51, 136-138.	1.8	10
23	Potential loss of prognostic significance of minimal residual disease assessment after RĀCHOPĀbased induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. <i>Hematological Oncology</i> , 2018, 36, 773-778.	1.7	10
24	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742.	1.8	10
25	Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 393-393.	1.4	10
26	Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 9.	2.7	9
27	Single-agent ibrutinib in RESONATE-2Ā,Ā and RESONATEĀ,Ā versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	1.8	9
28	LowĀdose fludarabine and cyclophosphamide combined with rituximab in the firstĀline treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): longĀterm results of project QĀlite by the Czech CLL Study Group. <i>British Journal of Haematology</i> , 2021, 193, 769-778.	2.5	9
29	Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 421-427.	0.9	8
30	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. <i>Blood</i> , 2018, 132, 691-691.	1.4	8
31	Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. <i>Leukemia Research</i> , 2019, 79, 17-21.	0.8	7
32	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	1.3	7
33	RealĀworld data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <sc>GOĀCLLEAR</sc> Study by the Czech <sc>CLL</sc> Study Group. <i>Hematological Oncology</i> , 2020, 38, 509-516.	1.7	7
34	Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks. <i>Scientific Reports</i> , 2021, 11, 322.	3.3	6
35	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <i>Cancers</i> , 2021, 13, 3134.	3.7	6
36	Practical approach to management of chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 448-456.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	2.2	5
38	Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8015-8015.	1.6	5
39	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. <i>Neoplasma</i> , 2014, 62, 585-592.	1.6	4
40	External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. <i>British Journal of Haematology</i> , 2021, 193, 133-137.	2.5	4
41	Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 152-156.	0.5	3
42	Recommendations for chronic lymphocytic leukaemia diagnosis and therapy 2021. <i>Transfuze A Hematologie Dnes</i> , 2021, 27, 91-106.	1.0	2
43	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
44	3.6 The Role of Imaging Methods in CLL: Significant Internal Lymphadenopathy is Frequent and Associated with Shorter Overall Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S199-S200.	0.4	1
45	Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation?. <i>Archives of Medical Science</i> , 2019, 15, 1443-1453.	0.9	1
46	Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S280-S281.	0.4	1
47	CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S220-S221.	0.4	1
48	Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13421.	3.4	1
49	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
50	Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7538-7538.	1.6	1
51	Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4629-4629.	1.4	0
52	The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen. <i>Blood</i> , 2012, 120, 4603-4603.	1.4	0
53	Rituximab and High-Dose Dexamethasone (R-dex) Is Effective In The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4184-4184.	1.4	0
54	Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results. <i>Blood</i> , 2014, 124, 1720-1720.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia. Blood, 2015, 126, 5298-5298.	1.4	0
56	Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. Onkologie (Czech) Tj ETQq0 0 0 rgBT <sub>1</sub> /Overlock 10 Tf 50	0.1	0
57	Treatment of repeatedly relapsing chronic lymphocytic leukemia. Onkologie (Czech Republic), 2018, 12, 139-143.	0.1	0
58	Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg. Blood, 2019, 134, 1766-1766.	1.4	0
59	Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2020, 164, 425-434.	0.6	0
60	Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2â„¢ with the Cllear and Lyon-Sud Rw Databases. Blood, 2021, 138, 4679-4679.	1.4	0
61	Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia. Onkologie (Czech Republic), 2022, 16, 151-154.	0.1	0